Baxter International Inc. Securities Lawsuit Investigation
Shamis & Gentile P.A. is investigating potential claims against Baxter International (BAX) for allegedly misleading investors about its Novum IQ infusion pump.Summary
Shamis & Gentile P.A. is investigating a potential class action lawsuit against Baxter International, Inc. (BAX) concerning alleged misrepresentations regarding the safety and commercial success of its Novum IQ Large Volume Pump. The firm alleges that Baxter misled investors between February 23, 2022, and July 30, 2025, by portraying the Novum IQ as a “best in class” platform with advanced safety features, while allegedly knowing the device had systemic problems, including underinfusion, overinfusion, and complete non-delivery of fluids. The complaint states Baxter received reports of seventy-nine serious injuries and two patient deaths related to the device. Concerns became public in April 2025 with a whistleblower report, leading to a Class I recall by the FDA and a voluntary pause of Novum IQ sales on July 31, 2025. Following this announcement, Baxter’s stock price fell 22.4%, causing significant investor losses. Investors who purchased Baxter securities during the class period may be eligible to join the lawsuit and seek compensation, with a lead plaintiff deadline of December 15, 2025.
(Source：Claim Depot)